Patents by Inventor Vuong Trieu

Vuong Trieu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190275062
    Abstract: Device and method for improving the effectiveness of osteopathic pain therapy by monitoring one or more pharmacokinetic parameters of the subject with a point-of-care device after pain drug administration. In one embodiment, the pain drug is celecoxib and the pharmacokinetic parameter is AUC.
    Type: Application
    Filed: May 20, 2019
    Publication date: September 12, 2019
    Applicant: Marina Biotech, Inc.
    Inventor: Vuong Trieu
  • Publication number: 20190201508
    Abstract: Methods for treating cancers, such as breast cancer or skin cancer, using an ACE or ARB, or a combination of celecoxib and olmesartan.
    Type: Application
    Filed: November 30, 2018
    Publication date: July 4, 2019
    Applicant: Marina Biotech, Inc.
    Inventor: Vuong Trieu
  • Publication number: 20190125727
    Abstract: The invention provides compositions and methods for individualized therapy of arthritic pain without causing edema, using non-steroidal anti-inflammatory drugs (COX-2 inhibitor) in combination with a diuretic drug.
    Type: Application
    Filed: October 29, 2018
    Publication date: May 2, 2019
    Applicant: Marina Biotech, Inc.
    Inventor: Vuong Trieu
  • Publication number: 20190091243
    Abstract: Methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (COX-2 inhibitor). Said methods comprise basing COX-2 inhibitor dose on each patient's pharmacokinetic response to said COX-2 inhibitor.
    Type: Application
    Filed: November 30, 2018
    Publication date: March 28, 2019
    Applicant: Marina Biotech, Inc.
    Inventor: Vuong Trieu
  • Publication number: 20190070201
    Abstract: Compositions and methods for individualized therapy of pain using a non-steroidal anti-inflammatory drug (NSAID) and an anti-hypertensive without inducing intolerable edema. Said methods comprise basing NSAID/anti-hypertensive dose on each patient's pharmacokinetic response to said NSAID.
    Type: Application
    Filed: November 7, 2018
    Publication date: March 7, 2019
    Applicant: Marina Biotech, Inc.
    Inventor: Vuong Trieu
  • Publication number: 20190030049
    Abstract: Device and method for improving the effectiveness of osteopathic pain therapy by monitoring one or more pharmacokinetic parameters of the subject with a point-of-care device after pain drug administration. In one embodiment, the pain drug is celecoxib and the pharmacokinetic parameter is AUC.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Applicant: Marina Biotech, Inc.
    Inventor: Vuong Trieu
  • Publication number: 20190022020
    Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Vuong TRIEU
  • Publication number: 20180289620
    Abstract: The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.
    Type: Application
    Filed: January 24, 2018
    Publication date: October 11, 2018
    Inventors: NEIL P. DESAI, Chunlin TAO, Tapas DE, Sherry Xiaopei CI, Vuong TRIEU
  • Patent number: 10053504
    Abstract: The invention provides compositions comprising SPARC binding ScFv and its use.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: August 21, 2018
    Assignee: ABRAXIS BIOSCIENCE, LLC
    Inventor: Vuong Trieu
  • Publication number: 20180221289
    Abstract: In one aspect, the invention provides therapeutic agent nanoparticles coated with cholesteryl esters, formulations of the nanoparticles suitable for injection, methods for administering therapeutic agents and for treating diseases and conditions treatable by the therapeutic agents using the formulations. In a related aspect, the invention provides synthetic high density lipoprotein nanoparticles useful for therapeutic agent delivery, and methods for their preparation and use.
    Type: Application
    Filed: August 8, 2016
    Publication date: August 9, 2018
    Applicant: Autotelic LLC
    Inventor: Vuong Trieu
  • Publication number: 20180153818
    Abstract: Phospholipid-coated nanoparticles containing a therapeutic agent, compositions that include the nanoparticles, and methods for making and using the nanoparticles and compositions.
    Type: Application
    Filed: September 14, 2017
    Publication date: June 7, 2018
    Applicant: Autotelic LLC
    Inventors: Vuong Trieu, Tapas K. De
  • Patent number: 9989543
    Abstract: This disclosure provides compositions, including antibodies or fragments or derivatives thereof, and related devices and methods effective for detecting and quantifying olmesartan in a sample. The compositions, devices, and methods can be applied to improve the effectiveness of hypertension therapy by monitoring a subject's compliance by determining one or more pharmacokinetic parameters of the subject with a point-of-care device after antihypertensive drug administration. In one embodiment, the antihypertensive drug is olmesartan and the pharmacokinetic parameter is AUC.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: June 5, 2018
    Assignee: AUTOTELIC, LLC
    Inventor: Vuong Trieu
  • Patent number: 9964551
    Abstract: Optimized affinity reagent compositions for binding paclitaxel, such as antibodies, antibody fragments, and antibody derivatives, related methods of use, and related kits, are provided herein. Affinity reagents that comprise one or more complementary determining regions (CDRs) optimized from anti-paclitaxel antibodies antibody 8A10 and 3C6 are specifically provided. The disclosed affinity reagents are useful for binding and detecting paclitaxel in a sample, such as for determining or optimizing future doses of paclitaxel in a subject that was previously administered with paclitaxel.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: May 8, 2018
    Assignee: AUTOTELIC, LLC
    Inventors: Vuong Trieu, Chulho Park
  • Patent number: 9963703
    Abstract: Provided herein are composition for sensitizing tumors to anti-tumor therapies. The compositions include antisense oligonucleotides against TGF?2, wherein the compositions sensitize tumors to anti-tumor therapies. Also provided herein are method for treating cancer using the compositions described herein.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: May 8, 2018
    Inventor: Vuong Trieu
  • Publication number: 20180074063
    Abstract: The present invention relates to biomarkers, methods, devices, reagent, systems and kits for the detection, diagnosis of ovarian cancer as well as for the monitoring of ovarian cancer progression and for monitoring the progress of various cancer treatmeats including ovarian cancer. The present invention also relates to point-of-care testing (POCT) and methods for determining concentrations of biomarkers in a subject.
    Type: Application
    Filed: May 16, 2017
    Publication date: March 15, 2018
    Applicant: Autotelic LLC
    Inventor: Vuong Trieu
  • Publication number: 20170342419
    Abstract: Provided herein are composition for sensitizing tumors to anti-tumor therapies. The compositions include antisense oligonucleotides against TGF?2, wherein the compositions sensitize tumors to anti-tumor therapies. Also provided herein are method for treating cancer using the compositions described herein.
    Type: Application
    Filed: August 4, 2017
    Publication date: November 30, 2017
    Applicant: Autotelic LLC
    Inventor: Vuong TRIEU
  • Publication number: 20170326109
    Abstract: The invention provides compositions and methods for individualized therapy of arthritic pain without causing edema, using a non-steroidal anti-inflammatory drugs (COX-2 inhibitor) in combination with a diuretic drug.
    Type: Application
    Filed: April 18, 2017
    Publication date: November 16, 2017
    Applicant: Autotelic LLC
    Inventor: Vuong Trieu
  • Publication number: 20170312347
    Abstract: Methods for treating cancers, such as breast cancer or skin cancer, using an ACE or ARB, or a combination of celecoxib and olmesartan.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 2, 2017
    Applicant: Autotelic LLC
    Inventor: Vuong Trieu
  • Publication number: 20170276680
    Abstract: Methods, devices, reagent, systems and kits for the detection, diagnosis of ovarian cancer as well as for the monitoring of ovarian cancer progression and for monitoring the progress of ovarian cancer treatments using BNP as a biomarker.
    Type: Application
    Filed: June 12, 2017
    Publication date: September 28, 2017
    Applicant: Autotelic LLC
    Inventor: Vuong Trieu
  • Patent number: 9763892
    Abstract: Phospholipid-coated nanoparticles containing a therapeutic agent, compositions that include the nanoparticles, and methods for making and using the nanoparticles and compositions.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: September 19, 2017
    Assignee: Autotelic LLC
    Inventors: Vuong Trieu, Tapas K. De